Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$290.54
neg -0.94
-0.32%
Today's Range: 289.76 - 296.00 | BIIB Avg Daily Volume: 1,803,400
Last Update: 04/17/14 - 4:00 PM EDT
Volume: 1,283,744
YTD Performance: 3.92%
Open: $291.00
Previous Close: $291.48
52 Week Range: $194.66 - $358.89
Oustanding Shares: 236,393,930
Market Cap: 68,904,102,716
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 14 14 14
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.63 1.60 1.60 1.60
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 45.06
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
45.06 37.30 29.01
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-2.33% 42.37% 250.22%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.70 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $2.58 $2.68 $11.29 $14.56
Number of Analysts 4 4 4 4
High Estimate $2.79 $2.73 $11.73 $15.69
Low Estimate $2.48 $2.62 $11.13 $13.25
Prior Year $1.96 $2.30 $8.93 $11.29
Growth Rate (Year over Year) 31.38% 16.30% 26.40% 28.99%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 16, 2014 | 11:45 AM EDT

Algos think faster and react faster than humans can.

By

Jim Cramer

 | Apr 14, 2014 | 11:49 AM EDT

Cautionary tales that the IPO window might be closing at last.

By

Dan Fitzpatrick

 | Apr 9, 2014 | 8:00 AM EDT

These stocks are broken -- and you can't un-break them

bullishBiogen Idec upgraded at BMO

Mar 6, 2014 | 7:55 AM EST

BIIB was upgraded to Outperform, BMO Capital said. $422 price target. Company has attractive near-term growth opportunities in its product pipeline. 

bullishBiogen Idec numbers increased at Leerink

Feb 20, 2014 | 8:14 AM EST

BIIB estimates were raised through 2015, Leerink Swann said. Estimates also raised, given higher expected Elocate sales. Outperform rating and new $351 price target. 

By

Jim Cramer

 | Feb 14, 2014 | 1:55 PM EST

These sectors have shown some fight.

By

Jim Cramer

 | Feb 14, 2014 | 11:12 AM EST

And valuation of individual stocks comes back into play.

By

Jim Cramer

 | Feb 11, 2014 | 12:59 PM EST

I like living, breathing examples of growth stocks going right.

By

Timothy Collins

 | Jan 31, 2014 | 2:15 PM EST

I'm using the market's push lower to buy strong charts.

By

Jim Cramer

 | Jan 30, 2014 | 12:50 PM EST

These types of companies are winners today.

There were nice reversal-type candles on the weekly charts of the major indices. The DOW a...
A number of stocks on my watch lists are attempting to form positive candles a key suppor...
While last week was a day to pull the plug and contemplate where the market was headed, I ...
Shares of TSLA have formed multiple hammer candles at a key level of support defined by: t...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.